scispace - formally typeset
Open AccessJournal ArticleDOI

Phenotypic Diversity and Clinico-Hematological Profile of Hb E-Beta Thalassemic Children

Reads0
Chats0
TLDR
In this study,phenotypic diversity of Hb E-β thalassemia children were analysed by studying the clinical and hematological parameters and there was no significant correlation between severity of the disease and HbF level.
Abstract
Hb E-Beta thalassemia is a disease with marked clinical diversity. In this study, phenotypic diversity of Hb E-β thalassemia children were analysed by studying the clinical and hematological parameters. This was a cross sectional study done in one and a half year period in the department of Pediatrics of a tertiary care teaching hospital. Participants were 62 Hb E-β thalassemic children of age group 1 month to 18 years coming to the Thalassemia day care centre for blood transfusion. Data collected from history, examination findings and investigation reports were analyzed. M:F ratio was 1.07:1; 71% children were above 5 years of age. 90.3% children were Hindu. In 66.1% children, Hb level was below 5 gm/dl at the time of diagnosis. Mean HbF level was 32.6% ± 11.2. Stunting was seen in 64.5%. Average liver and spleen size were 2.5 and 4.4 cm respectively. Beside pallor, most common clinical findings were splenomegaly (93.5%), facial deformity (87%), dusky skin color (82.5%) and hepatomegaly (75.8%). 1.6% children were mild, 43.5% children were moderate and 54.8% children were of severe type. In our study there was no significant correlation between severity of the disease and HbF level (r = 0.0853, p = 0.0509). Age at the time of diagnosis, hemoglobin level at the time of first transfusion, age at receiving first blood transfusion, requirement of blood transfusion, spleen size and growth, are some factors affecting severity of the disease. But severity cannot be assessed by considering only one clinical or hematological parameter but by considering several parameters together.

read more

Citations
More filters
Journal ArticleDOI

A novel mutation Hb jiangnan[β3(NA3) Leu→Lys, HBB:c.10_11delinsAA] causing elevated Hb A2 level

TL;DR: The Hb variant is named Hb Jiangnan according to the place of residence of the proband, so it can be separated by HPLC but not CE, and can cause an increased level of Hb A2.
Journal ArticleDOI

Hemoglobin EE disease in young Laotian children: Hematologic features and the contributions of genetic variations to Hb F expression

TL;DR: The wide variation in hemoglobin (Hb) F levels has been observed in patients with hemoglobin EE disease in this article , and the effect of genetic variants on Hb F expression in young children with Hb EE disease was investigated.
References
More filters
Journal ArticleDOI

Beta-thalassemia

TL;DR: A group of hereditary blood disorders characterized by anomalies in the synthesis of the beta chains of hemoglobin resulting in variable phenotypes ranging from severe anemia to clinically asymptomatic individuals.
Journal Article

Haemoglobinopathies in Southeast Asia

TL;DR: It is possible to set a strategy for prevention and control of thalassaemia, which includes population screening for heterozygotes, genetic counselling and foetal diagnosis with selective abortion of affected pregnancies.
Journal ArticleDOI

Prevalence of β-thalassemia and other haemoglobinopathies in six cities in India: a multicentre study

TL;DR: This is the first large multicentre study covering cities from different regions of the country for screening for β-thalassemia carriers and other haemoglobinopathies where uniform protocols and methodology was followed and quality control ensured by the co-ordinating centre.
Journal ArticleDOI

The Hemoglobin E Thalassemias

TL;DR: Hemoglobin E (HbE) is an extremely common structural hemoglobin variant that occurs at high frequencies throughout many Asian countries and comprises approximately 50% of the clinically severe β-thalassemia disorders.
Journal ArticleDOI

Hemoglobin E Syndromes

TL;DR: It is important to distinguish Hb E disorders diagnostically because of this marked difference in clinical course among different genotypes, and patients are excellent candidates for Hb F-modulating agents because moderate changes in hemoglobin may result in marked improvement in phenotype.
Related Papers (5)